Overview
- Cash discounts will begin by January through the TrumpRx program and Medicare changes are slated for mid-2026, with Medicaid expanding as states opt in.
- Novo Nordisk and Eli Lilly also pledged entry-level oral GLP-1 pills at $149 per month if those products win U.S. approval.
- Commercial insurers are expected to access prices about 25% below current cash rates, which physicians say could spur employers to restore coverage.
- Obesity specialists expect more patients to start treatment but warn many may stop due to side effects, ongoing costs and the need for long-term use.
- Entry prices apply to starter doses, with Zepbound reaching about $450 per month at higher doses after prior cash prices often exceeded $500.